Annual report [Section 13 and 15(d), not S-K Item 405]

Intangible Assets and Impairment of Long-Lived Assets (Tables)

v3.25.1
Intangible Assets and Impairment of Long-Lived Assets (Tables)
 12 Months Ended
Dec. 31, 2024
Intangible Assets and Impairment of Long-Lived Assets [Abstract]  
Schedule of Intangible Assets

Intangible assets at December 31, 2024 and 2023 consisted of the following: 

 

    Useful   December 31,     December 31,  
    Life (years)   2024     2023  
Source code and intellectual property   3   $ 7,622,041     $
-
  
Licensed Patents   20     530,651       599,686  
Technology license   20     1,607,667       1,562,744  
                     
Intangible assets         9,760,359       2,162,430  
Less: accumulated amortization         (611,776 )     (542,860 )
Less: accumulated impairment loss         (1,526,542 )    
-
  
                     
Intangible assets, net       $ 7,622,041     $ 1,619,570  
Schedule of Losses for the IP R&D Assets

The following is a summary of IP R&D activity for the year ended December 31, 2023 for the Company, which includes the recorded losses for the IP R&D assets described above.

 

    CBR
Pharma IP
R&D Assets		     180 LP IP
R&D
Assets		     Consolidated
IP R&D
Assets		  
                   
Balance, December 31, 2023   $
           -
     $ 9,063,000       9,063,000  
Impairment of IP R&D assets    
-
       (9,063,000 )     (9,063,000 )
                         
Balance, December 31, 2023   $
-
     $
-
     $
-